Jentashapir Journal of Cellular and Molecular Biology, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 13, 2025

Context: Recent advances in induced pluripotent stem cells (iPSCs), CRISPR-Cas9 gene editing, nanotechnologies, and artificial intelligence have revolutionized regenerative medicine (RM) as a transformative field for tackling difficult medical problems. These breakthroughs promise specific treatments, proper restoration of tissue function, substantial improvements the quality life patients whose ailments cannot yet be cured. This review explores cutting-edge advancements RM platforms such cell therapy, 3D bioprinting, nanotechnology. The study also aims to shed light on challenges clinical translation policy implications, which are crucial fostering sustainable progressive discipline. Evidence Acquisition: manuscript draws research development application technologies. It synthesizes data cells, engineering, vitro organoid industry, (AI), nanotechnology that illustrate therapeutic potential. identify ethical, regulatory, practical hurdles translating from practice. Results: Breakthroughs those iPSC-derived organoids, nanostructured materials exhibit significant preclinical settings. Platforms organ-on-chip AI tools further enhance drug discovery treatment monitoring, while biomaterials scaffold-based approaches repair regeneration. Nevertheless, despite these advances, persist regarding scale-up, safety, ethical considerations. Conclusions: Innovations represent paradigm shift purely symptomatic treatments restorative therapies. Successful integration into practice will require multidisciplinary collaborative work, imposition rigorous safety protocols, enabling regulatory frameworks. Addressing would enable realize its true potential foundation 21st-century healthcare.

Язык: Английский